301 related articles for article (PubMed ID: 28424818)
1. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
2. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
[TBL] [Abstract][Full Text] [Related]
3. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
Honickel M; Braunschweig T; Rossaint R; Schöchl H; Grottke O
Transfusion; 2019 Apr; 59(4):1376-1387. PubMed ID: 30586470
[TBL] [Abstract][Full Text] [Related]
5. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
6. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
Honickel M; Braunschweig T; Rossaint R; Stoppe C; Ten Cate H; Grottke O
Anesthesiology; 2017 Nov; 127(5):852-861. PubMed ID: 28857806
[TBL] [Abstract][Full Text] [Related]
7. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
[TBL] [Abstract][Full Text] [Related]
8. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
9. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
Hofer S; Philipsenburg C; Weigand MA; Brenner T
A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
[TBL] [Abstract][Full Text] [Related]
10. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
Lindeman E
Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
[TBL] [Abstract][Full Text] [Related]
11. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Sheikh-Taha M
Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
14. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
17. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
18. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
[TBL] [Abstract][Full Text] [Related]
19. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
20. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
